ROSWELL PARK CANCER INSTITUTE announced the formation of Global Biotechnology & Cancer Therapeutics, a for-profit company that will support biotech and life-sciences startups. “GBCT will allow outside biotechnology companies to partner with a scientifically respected entity that will provide infrastructure for drug development and investment — everything from clinical trials to anticancer agents and vaccines,...
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
